Sara González

CLINICAL EFFICACY OF SEQUENTIAL TREATMENTS IN METASTATIC KRASG12C-MUTATED COLORECTAL CANCER

News /

This multicenter clinical trial evaluated the clinical efficacy of sequential treatments in patients with metastatic colorectal cancer with G12C mutation of the KRAS gene who received intensive first-line double or triple first-line chemotherapy (including irinotecan- or oxaliplatin-based chemotherapy). In the development of the trial, only moderate overall response rates were observed with first-line double or […]

CLINICAL EFFICACY OF SEQUENTIAL TREATMENTS IN METASTATIC KRASG12C-MUTATED COLORECTAL CANCER Read More »

PROGNOSTIC IMPACT OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH LMA IN FIRST REMISSION RECEIVING ORAL AZACITIDINE MAINTENANCE.

News /

The trial conducted by Hartmut Döhner and his research group has shown that, compared to placebo, oral azacitidine improved overall survival in patients with acute myeloid leukemia (AML) in first remission after chemotherapy who were not candidates for stem cell transplantation. This analysis found that the azacitidine-associated survival improvement was independent of NPM1 and FLT3

PROGNOSTIC IMPACT OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH LMA IN FIRST REMISSION RECEIVING ORAL AZACITIDINE MAINTENANCE. Read More »

ctDNA to Guide Panitumumab Rechallenge in Metastatic Colorectal Cancer

News /

Monoclonal antibodies against epidermal growth factor receptor (EGFR) are approved for the treatment of metastatic RAS-like colorectal cancer (WT), but the emergence of resistance mutations restricts their efficacy. Previous studies demonstrated that mutant alleles of RAS, BRAF and EGFR, which appear in circulating tumor DNA (ctDNA) during blockade, decrease upon withdrawal of therapy. CHRONOS hypothesized that

ctDNA to Guide Panitumumab Rechallenge in Metastatic Colorectal Cancer Read More »

PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER

News /

Javier Cortes and his research team have conducted a clinical trial, currently in phase 3, to study the effect of adding pembrolizumab to standard chemotherapy in patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more. The results show that the

PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER Read More »

DIAGNOSIS AND MANAGEMENT OF AML IN ADULTS: 2022 ELN RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT PANEL

News /

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease

DIAGNOSIS AND MANAGEMENT OF AML IN ADULTS: 2022 ELN RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT PANEL Read More »

ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION

News /

Adagrasib is a KRAS G12C mutation inhibitor that has been studied for the past several years in patients with these mutations. This drug is similar to Sotorasib, which is FDA approved and available for use. Adagrasib appears to have good efficacy in a subset of patients with non-small cell lung cancer with the G12C mutation

ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION Read More »

IMMUNOTHERAPY SHOWS 100% RESPONSE RATE IN CERTAIN RECTAL CANCER PATIENTS

News /

Rectal cancer, a rare neoplasm related to colon cancer, is usually diagnosed at an advanced stage, when it is more difficult to treat. The standard treatment for locally advanced rectal cancer is neoadjuvant (preoperative) chemotherapy and radiation therapy to shrink tumors, followed by surgery to remove all or part of the rectum, which may require

IMMUNOTHERAPY SHOWS 100% RESPONSE RATE IN CERTAIN RECTAL CANCER PATIENTS Read More »

FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER

News /

On May 4, 2022, the Food and Drug Administration (FDA) approved Enhertu (trastuzumab deruxtecan) treatment from Daiichi Sankyo Company and AstraZeneca, for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more treatment regimens based on anti-HER2 therapies. The treatment is approved in the metastatic setting or in the

FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER Read More »

NEW DRUG CANDIDATE TO BLOCK TUMOR STEM CELLS TUMOR STEM CELLS

News /

An international consortium led by IRB Barcelona and the company Merus has discovered MCLA-158, an antibody that targets cancer stem cells in solid tumors and prevents metastasis in experimental models. The MCLA-158 antibody, commercially known as Petosemtamab, is a bispecific antibody that recognizes two distinct proteins on the surface of cancer stem cells, namely EGFR

NEW DRUG CANDIDATE TO BLOCK TUMOR STEM CELLS TUMOR STEM CELLS Read More »

FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM

News /

On April 5, 2022, the Food and Drug Administration (FDA) approved alpelisib (Vijoice, Novartis Pharmaceuticals) treatment for adult and pediatric patients aged two years and older with severe manifestations of the spectrum of PIK3CA-related overgrowth syndromes (PROS) requiring systemic treatment. Efficacy was evaluated using a clinical trial of 37 patients over two years of age

FDA APPROVES ALPELISIB FOR PIK3CA-RELATED OVERGROWTH SPECTRUM Read More »

Descargar más información